scholarly article | Q13442814 |
P50 | author | Jianji Pan | Q82177517 |
Tianzhu Lu | Q88826123 | ||
Shaojun Lin | Q90217294 | ||
Qiaojuan Guo | Q90247416 | ||
Jingfeng Zong | Q117278902 | ||
P2093 | author name string | Ying Su | |
Yiping Chen | |||
Yunbin Ye | |||
Jieyu Li | |||
Yuhong Zheng | |||
Wansong Lin | |||
P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
Advances in targeting cell surface signalling molecules for immune modulation | Q36973787 | ||
Nasopharyngeal carcinoma: current management, future directions and dental implications | Q37025339 | ||
Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy | Q37141483 | ||
Host-tumor interactions in nasopharyngeal carcinomas | Q37976234 | ||
Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. | Q38583301 | ||
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. | Q38954827 | ||
Epstein-Barr virus infection and nasopharyngeal carcinoma | Q40046633 | ||
Clinical significance of PD-L1+ exosomes in plasma of Head and Neck Cancer patients | Q47256356 | ||
Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis. | Q49309172 | ||
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. | Q50993649 | ||
Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. | Q53097632 | ||
The Microenvironment in Epstein-Barr Virus-Associated Malignancies. | Q54236409 | ||
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response | Q59070397 | ||
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
Immune checkpoint inhibitors: recent progress and potential biomarkers | Q60302456 | ||
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial | Q60685639 | ||
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab. | Q64925763 | ||
Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC): A preliminary study | Q90418185 | ||
Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients | Q91004899 | ||
Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer | Q91083851 | ||
Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker | Q91325361 | ||
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials | Q91433225 | ||
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy | Q91520697 | ||
Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients | Q91553095 | ||
Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas | Q91914786 | ||
Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer | Q92322348 | ||
Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy | Q92625292 | ||
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics | Q93129314 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
P6216 | copyright status | copyrighted | Q50423863 |
P304 | page(s) | 1757-1765 | |
P577 | publication date | 2020-02-26 | |
P1433 | published in | OncoTargets and Therapy | Q7092081 |
P1476 | title | High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma | |
P478 | volume | 13 |
Q98288422 | TET2 suppresses nasopharyngeal carcinoma progression by inhibiting glycolysis metabolism | cites work | P2860 |
Search more.